Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Integrative analysis of ATAC-seq and RNA-seq for cells infected by human T-cell leukemia virus type 1.
PLoS Comput Biol
January 2025
Department of Hematology, Rheumatology and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy (HAM) after a long latent period in a fraction of infected individuals. These HTLV-1-infected cells typically have phenotypes similar to that of CD4+T cells, but the cell status is not well understood. To extract the inherent information of HTLV-1-infected CD4+ cells, we integratively analyzed the ATAC-seq and RNA-seq data of the infected cells.
View Article and Find Full Text PDFCharacterization of HTLV-1 Infectious Molecular Clone Isolated from Patient with HAM/TSP and Immortalization of Human Primary T-Cell Lines.
Viruses
November 2024
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA.
Article Synopsis
- HTLV-1 is linked to diseases like adult T-cell leukemia and HTLV-1-associated myelopathy, prompting researchers to isolate a molecular clone from a patient with HAM/TSP.
- This clone exhibits unique genetic features and viral mRNA patterns, indicating a potential connection to the development of HAM/TSP.
- The study finds that while direct infection of primary T cells with HTLV-1 clones leads to limited cell growth, transmission from dendritic cells enhances long-term proliferation and supports latent infections.
Antiviral immune response against HTLV-1 invalidates T-SPOT.TB results in patients with HTLV-1-positive rheumatic diseases.
Front Immunol
November 2024
Division of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Background: T-SPOT.TB, one of the screening tests for latent tuberculosis infection (LTBI), yields invalid results in human T-cell leukemia virus type 1 (HTLV-1)-positive patients with rheumatoid arthritis. However, the detailed mechanisms behind this invalidation are unclear.
View Article and Find Full Text PDFDoes Antiretroviral Therapy Prevent Human T-Lymphotropic Virus 1 Transmission From a Seropositive Donor to a Kidney Transplant Recipient? A Case Report and Literature Review.
Exp Clin Transplant
August 2024
From the Infectious Diseases Department, and the Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
Human T-lymphotropic virus 1 produces a latent infection and disease with poor prognosis. Although its transmission during solid-organ transplant and development of the disease has been described, it is not clear whether antiretroviral treatment could prevent it. We report the first kidney transplant of a donor with human T-lymphotropic virus positivity to a negative recipient who was under antiretroviral treatment without evidence of transmission.
View Article and Find Full Text PDF[Tax-targeted dendritic cell vaccine therapy for long-term remission of adult T-cell leukemia-lymphoma].
Rinsho Ketsueki
August 2023
Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center.
Adult T-cell leukemia-lymphoma (ATL) is a highly aggressive peripheral T-cell neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1) infection occurring in approximately 5% of patients after prolonged latent period. ATL relapses within a short period despite its transient response to multiagent chemotherapy and the prognosis is extremely poor due to anticancer drug resistance and immunodeficiency. Although novel agents with different mechanisms, such as molecular targeted agents, have improved the prognosis, the number of cured patients remains limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!